PMID- 21923812
OWN - NLM
STAT- MEDLINE
DCOM- 20120322
LR  - 20171116
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 25
IP  - 10
DP  - 2011 Oct
TI  - Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic 
      cell neoplasm after allogeneic bone marrow transplantation: FISH analysis 
      revealed loss of 11q.
PG  - 1225-9
LID - 10.1111/j.1468-3083.2010.03922.x [doi]
AB  - BACKGROUND: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare entity 
      characterized by a CD4+/CD56+/CD123+ immunophenotype and a fatal clinical course. 
      The average survival of 12-14 months may be prolonged by allogeneic bone marrow 
      transplantation (BMT). OBJECTIVES: We report about a male patient who suffered 
      from BPDCN with a typical histology and co-expression of CD4/CD123 and a CD56 
      expression by 80% of the tumour cells. The cutaneous tumour relapse after 
      chemotherapy and allogeneic BMT was completely negative for CD56. METHODS: We 
      performed interphase fluorescence in situ hybridization (FISH) analysis of tumour 
      tissue, asserved before and after BMT, using specific probes for chromosome 11, 
      which encompass the CD56 gene region. RESULTS: The tumour cells revealed a 
      partial loss of 11q as well as a monosomy of chromosome 11. CONCLUSION: This case 
      demonstrates for the first time that loss of CD56 expression can also occur as a 
      secondary event after chemotherapy and BMT. In our case, DNA loss of 11q23 could 
      be responsible for the negativity of 20% of tumour cells as observed before 
      chemotherapy. However, the complete loss of CD56 expression in the relapsed 
      tumour cannot be explained by the loss of 11q23 alone. Additional factors such as 
      chemotherapy-induced mutations might also have contributed.
CI  - (c) 2010 The Authors. Journal of the European Academy of Dermatology and 
      Venereology (c) 2010 European Academy of Dermatology and Venereology.
FAU - Mitteldorf, C
AU  - Mitteldorf C
AD  - Department of Dermatology, Georg August University Gottingen, Germany. 
      christina.mitteldorf@klinikum-hildesheim.de
FAU - Bertsch, H P
AU  - Bertsch HP
FAU - Baumgart, M
AU  - Baumgart M
FAU - Haase, D
AU  - Haase D
FAU - Wulf, G
AU  - Wulf G
FAU - Schon, M P
AU  - Schon MP
FAU - Rosenwald, A
AU  - Rosenwald A
FAU - Neumann, C
AU  - Neumann C
FAU - Kaune, K M
AU  - Kaune KM
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20101125
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (CD56 Antigen)
RN  - 5J49Q6B70F (Vincristine)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 9PHQ9Y1OLM (Prednisolone)
RN  - CHOEP protocol
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/pharmacology/therapeutic use
MH  - *Bone Marrow Transplantation
MH  - CD56 Antigen/genetics/*metabolism
MH  - Chromosomes, Human, Pair 11/drug effects/*genetics
MH  - Cyclophosphamide/administration & dosage
MH  - Dendritic Cells/*pathology
MH  - Doxorubicin/administration & dosage
MH  - Etoposide/administration & dosage
MH  - Fatal Outcome
MH  - Hematologic Neoplasms/*metabolism/pathology/*therapy
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Neoplasm Recurrence, Local/metabolism/pathology/therapy
MH  - Prednisolone/administration & dosage
MH  - Skin/metabolism/pathology
MH  - Skin Neoplasms/*metabolism/pathology/*therapy
MH  - Transplantation, Homologous
MH  - Vincristine/administration & dosage
EDAT- 2011/09/20 06:00
MHDA- 2012/03/23 06:00
CRDT- 2011/09/20 06:00
PHST- 2011/09/20 06:00 [entrez]
PHST- 2011/09/20 06:00 [pubmed]
PHST- 2012/03/23 06:00 [medline]
AID - 10.1111/j.1468-3083.2010.03922.x [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1225-9. doi: 
      10.1111/j.1468-3083.2010.03922.x. Epub 2010 Nov 25.